Answers are grounded in this paper and cite their sources.
The pharmacokinetics of kanamycin were studied in beagle dogs. A parenteral preparation of kanamycin sulphate (5% aqueous solution), which was given at a dosage level of 10 mg/kg of body weight, was the drug product used. The disposition curve which resulted from the intravenous administration of a single bolus dose of the drug was completely described by the biexponential equation: C p= 50e‐0.1977t+ 36.3e‐0.0128t where Cp represents concentration of the drug in the serum at time t (in minutes) and the experimental constants are mean values. Pseudo‐distribution equilibrium was rapidly attained and the apparent volumes of the central and peripheral compartments of the two‐compartment open model were the same (ca 125 ml/kg). Body clearance (mean ± S.D., n= 6) of kanamycin was 3.21 ±0.72 ml/kg/min. The half‐life of the drug was short (58.18 ± 18.43 min) and independent of the route of parenteral (intravenous and intramuscular) administration. Absorption of kanamycin from the intramuscular site was rapid, with a half‐time of 9.08 ± 1.10 min. A systemic availability of 89.1 ± 15.8% was obtained. Based on the bioavailability and disposition kinetics a dosage regimen consisting of the intramuscular injection of the dose (10 mg/kg) at 6 h intervals is proposed. An intravenous infusion rate of 48 μg/kgymin is predicted to establish a steady state serum concentration of 15 μg/ml, which is a therapeutic level of the antibiotic for susceptible micro‐organisms.
No takes yet. Share an insight, caveat, or question.
J. Desmond Baggot (1978) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: